In the Clinic
Transforming unprecedented RNAi technologies into treatment realities.
Developing the promise of a siRNA therapeutic candidate
CALAA-01, Calando's leading drug candidate, is a combination of RONDEL™ and a patented siRNA targeting the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target. Ribonucleotide reductase catalyzes the conversion of ribonucleosides to deoxyribonucleosides and is necessary for DNA synthesis and replication; it is a critical component in the proliferation of cancer cells. Calando's siRNA and CALAA-01 have demonstrated potent anti-proliferative activity across multiple types of cancer cells.
CALAA-01 Phase 1b Clinical Trial
This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in adults with solid tumors refractory to standard-of-care therapies. Patients who satisfy the inclusion and exclusion criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29, and 31 followed by 11 days of rest.
For information about the CALAA-01 clinical trials, please visit www.clinicaltrials.gov.
Originally developed by Insert Therapeutics, a Calando predecessor company, IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin (CPT) conjugated to a cyclodextrin polymer. IT-101 is based on the Cyclosert™ delivery platform developed by Insert scientists for small molecule drugs. Cyclosert™ is based on a linear cyclodextrin polymer similar to the one used in the RONDEL system. Both IT-101 and Cyclosert have been partnered with Cerulean Pharma, Inc., a Cambridge, MA based biotech company.